Drug intelligence / Profile preview

BI 11634

Development stage: Phase 1
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral (tablet), Oral (solution)

Overview

BI 11634 is a small molecule, orally administered direct inhibitor of factor Xa, an essential serine protease in the coagulation cascade. By inhibiting factor Xa, BI 11634 aims to prevent thrombin generation and subsequent clot formation. It has been investigated primarily for cardiovascular disorders related to thrombosis. The drug is metabolized predominantly by cytochrome P450 enzyme CYP3A4 in human liver microsomes[1][2][4][9]. Development and clinical studies have been conducted by Boehringer Ingelheim.

Other names: BI-11634 free baseBI11634 free baseBI 11634 free base

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on BI 11634.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 11634.

Explore the full profile